Trials / Completed
CompletedNCT04690335
Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challenge Model.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Meissa Vaccines, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research study is to evaluate whether the investigational, live attenuated, intranasally delivered vaccine MV-012-968 ('study vaccine') may have prophylactic efficacy against symptomatic RSV infection when administered to adults 18-45 years of age in the Human Viral Challenge model.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MV-012-968 | MV-012-968 is a recombinant, live attenuated RSV vaccine. |
| OTHER | Placebo | Saline solution |
Timeline
- Start date
- 2020-12-29
- Primary completion
- 2021-05-07
- Completion
- 2021-09-09
- First posted
- 2020-12-30
- Last updated
- 2022-08-04
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04690335. Inclusion in this directory is not an endorsement.